EXACT Therapeutics AS EXTX
OSL · Norway · Health Technology
NOK 0.6750+0.03 (+3.85%)
Market closed· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market closed· · NOK · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
European markets have recently shown mixed performance, with the pan-European STOXX Europe 600 Index declining slightly as investors weigh geopolitical developments and economic data. In this context, penny stocks—typically smaller or newer companies—continue to attract attention for their potential to offer both affordability and growth opportunities. Although the term "penny stocks" might seem outdated, these investments remain relevant for those looking beyond major market players,...
GE Medical Holding AB exercises all its Warrants in EXACT Therapeutics resulting in gross proceeds of NOK 33 million. Reference is made to the stock exchange announcement published on 27 January 2026 by EXACT Therapeutics, announcing that: The Trial Monitoring Committee has issued a positive conclusion for the pre-planned safety read-out and the phase 2 trial proceeds as planned.This triggers the option to exercise Warrants.Early, encouraging tumour shrinkage, and significant decrease in tumour
As the European market continues to thrive, with the STOXX Europe 600 Index reaching new highs and major indexes posting strong annual gains, investors are increasingly looking for opportunities in lesser-known areas. Penny stocks, though often considered a relic of past trading days, remain relevant by offering potential growth at lower price points. These smaller or newer companies can provide significant returns when supported by solid financials, and this article highlights three such...
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.